VTRS Q1 2022 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.2B-5.4% YoY

Gross Profit

$1.8B42.3% margin

Operating Income

$707M16.9% margin

Net Income

$399M9.5% margin

EPS (Diluted)

$0.33

QoQ Revenue Growth

-3.5%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$1.1B

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$53.5B

Total Liabilities

$33.0B

Stockholders' Equity

$20.4B

Cash & Equivalents

$752M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.2B	$4.4B	-5.4%
Gross Profit	$1.8B	$1.1B	+57.1%
Operating Income	$707M	-$266M	+365.7%
Net Income	$399M	-$1.0B	+138.5%

Revenue Segments

Brands

$2.6B61%

Generics

$1.2B30%

Complex GX and Biosimilars

$391M9%

Geographic Segments

Developed Markets Segment

$2.5B59%

Emerging Markets Segment

$705M17%

Greater China Segment

$573M14%

Japan, Australia and New Zealand Segment

$424M10%